MM-191: Association between IL17A Polymorphism and Clinicopathological Parameters in Egyptian Multiple Myeloma Patients

Abstract

<h3>Context</h3> Multiple myeloma (MM) is a B-cell lymphoproliferative disorder in which the bone marrow (BM) microenvironment plays a key role in pathogenesis. T-helper 17 cells present within the BM microenvironment and secrete the pro-inflammatory cytokine interleukin-17 (IL-17). Single nucleotide polymorphisms (SNPs) in IL-17 (<i>IL17A</i>) are found to be involved in the pathogenesis of many cancers and autoimmune diseases. <h3>Objective</h3> To investigate the role of <i>IL17A</i> SNPs in MM pathogenesis and their impact on clinical features of MM. <h3>Design</h3> A prospective study conducted on 77 MM patients and healthy controls of matched age and gender. <h3>Setting</h3> The study was carried out in the Oncology Center, Mansoura University. <h3>Patients</h3> Seventy-seven patients with MM (female; 46.8%, male; 53.2%) with mean age of 54.6 years. <h3>Interventions</h3> We obtained genomic DNA from 77 patients with MM and healthy controls and detected <i>IL17A-197</i> G/A (rs2275913) genotypes using the polymerase chain reaction-restriction fragment length polymorphism method. <h3>Main Outcome Measures</h3> The significance of <i>IL17A</i> polymorphism in relation to clinical data, laboratory data, and survival outcome. <h3>Results</h3> The <i>IL17A</i> polymorphism was not involved in susceptibility to MM in the Egyptian population, and there was no statistically significant association with gender (p=0.14), hypercalcemia (p=0.28), hypoalbuminemia (p=0.49), renal impairment (p=0.13), elevated LDH (p =0.62), osteolytic bone lesions (p=0.26), pathological fracture (p=0.96), plasmacytoma (p=0.42), and ISS stage III (p=0.26). <i>IL17A</i> polymorphism showed no statistically significant differences in OS (p=0.83) of MM patients, while there was a statistically significant worse OS among patients with thrombocytopenia (p=0.006), renal impairment (p=0.047), and ISS stage III (p=0.02). <h3>Conclusion</h3> In this study, <i>IL17A</i> polymorphism was not associated with susceptibility to MM and did not influence its severity. In addition, OS survival in MM patients was not affected by <i>IL17A</i> polymorphism.